TrialLeukemia2001

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.

G Visani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.